Top Markets
Coin of the day
Agile Therapeutics, Inc. Agile Therapeutics, Inc.

Agile Therapeutics, Inc.

AGRX
주식 순위 #38231
Agile Therapeutics, Inc. operates as a women's healthcare enterprise dedicated... Agile Therapeutics, Inc. operates as a women's healthcare enterprise dedicated to the research, development, and market introduction of prescription contraception in the United States. Its flagship product is Twirla (also known by its development code, AG200-15), a combined hormonal contraceptive delivered through a patch applied once weekly. The company is also progressing with several pipeline innovations, including variations of Twirla and other new products: AG200-15 Extended Regimen (ER): A regimen designed to limit a woman to four withdrawal bleeding occurrences annually. AG200-15 smaller patch (SmP): This iteration aims for shorter, lighter withdrawal bleeds and potentially enhanced contraceptive efficacy. AG200-15 ER SmP: A combined regimen that allows for an extended contraceptive cycle while simultaneously providing fewer, lighter annual bleeding episodes. P-Patch: A contraceptive patch containing only progestin, specifically intended for women who cannot or choose not to use estrogen. Agile Therapeutics, Inc. was founded in 1997 and is based in Princeton, New Jersey.
주가
$1.51
마지막 동기화: 2024-08-26
시가총액
$1.12M
변동 (1일)
0.00%
변동 (1년)
0.00%
국가
US
거래 Agile Therapeutics, Inc. (AGRX)

카테고리

Agile Therapeutics, Inc. (AGRX)의 매출
Jun 2024 기준 매출 TTM: $21.57M
Agile Therapeutics, Inc.의 최신 재무 보고서에 따르면 회사의 현재 수익 (TTM)은 $21.57M입니다. 2022년에 회사는 $10.88M의 수익을 올렸으며 이는 2021년의 $4.10M 대비 증가입니다. 수익은 상품이나 서비스를 판매하여 얻은 총 수입을 의미합니다. 수익과는 달리 비용이 차감되지 않습니다.
Agile Therapeutics, Inc.의 수익 기록 (2012 ~ 2026)
매년 말 매출
연도 매출 변화
2026 (TTM) $21.57M 10.08%
2023 $19.59M 80.02%
2022 $10.88M 165.40%
2021 $4.10M 447.53%
2020 $749.00K 0.00%
2019 0.00 0.00%
2018 0.00 0.00%
2017 0.00 0.00%
2016 0.00 0.00%
2015 0.00 0.00%
2014 0.00 0.00%
2013 0.00 0.00%
2012 0.00 0.00%
유사 기업 또는 경쟁사의 매출